Navigation Links
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:3/12/2008

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.

The poster presentation entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," is scheduled to be presented on June 2, 2008.

About ANX-510, or CoFactor

CoFactor is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-fluorouracil). Compared to leucovorin, CoFactor creates more stable binding between the active form of 5-FU and the target enzyme, thymidylate synthase. CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, potentially allowing 5-FU to work more effectively.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Genzyme Announces Presentation of New Positive Data on Carticel(R)
7. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...ound to Have Higher Sensitivity and Specificity, ...and was the preferred test in all ...Oct. 13 /- AT First Diagnostic LLC an...nostic test kits, today,announced that a recent ev...te of Research of the FirstVue(TM) HBSAG Test, was...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
(Date:10/10/2008).... 10 /- TriReme Medical Inc. (TMI),an... the CE (Conformite,Europeenne) marking and commer...ystem, a unique main vessel stent system specially...., Representing the next generation in bifurcatio...se in a quarter of the 2.2 million,angioplasty pro...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Clear racial discrepancies exist among patients with CKD 19735 1Clear racial discrepancies exist among patients with CKD 19735 2Widespread airbag use could result in dramatic cost savings for US trauma centers 19731 1Widespread airbag use could result in dramatic cost savings for US trauma centers 19731 2WebMD to Present at the Goldman Sachs Ninth Annual Internet Conference 19726 1BodyMedia Releases New 26 Improved SenseWear 28R 29 WMS Armband 19721 1BodyMedia Releases New 26 Improved SenseWear 28R 29 WMS Armband 19721 2
...News: Percentage of Working Age People with Diabet...oth PA and National Averages, PITTSBURGH, April 02...siness Group on Health (PBGH) announced today the,...nd quality of,care for people with Type 2 diabetes...for 2006 presents an overview of patient,demograph...
...ESDA, Md., April 1, 2007--Researchers report that ...prostate cancer,risk and that this common variatio...ate cancer cases in white men in the United States... the National,Cancer Institute (NCI), part of the ...in the Cancer Genetic Markers of Susceptibility,(C...
Other Medicine Technology:State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 2State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 3State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 4Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 2Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 3Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...e 'default mode,' or baseline condition when the b...ients with schizophrenia and this aberrant activit...in networks, a Yale School of Medicine researcher ...M.D., professor of psychiatry, said he and his col...
...cording to a study, diabetic women taking Actos ar...s. This was announced by Japan’s pharma giant//, T... this drug. A similar note of caution was issued a.... The study was conducted for more than three ye...
...tna: The battle against polio is far from over in ... alarming jump in the infectious disease// in a st...It is sad to admit that seven new polio cases surf... first week of February, despite the immunisation ...
...cent study revelations by a growing body of resear... and other minorities are less likely// to agree t...inal diseases. Explaining why, is the difficult p...anguage barriers, which make it hard for doctors t...
Other Medicine News:Health News:Brain’s "Default Mode" Awry in Schizophreni 2Health News:Seven Polio Cases Detected in Bihar 2Health News:Minorities Likely to Keep Fighting Death to the End 2
The standard pH Testing Application for POLYGRAM NET® (PNET) works with the Bravo™ Catheter-Free pH Monitoring System, Digitrapper™ Catheter-Based pH Recorder, and the Synectics Digit
...The Esophageal Manometry Application for POLYGRAM ...multiparametric recorder to record and analyze pre...uring esophageal manometry procedures. The PNET so...e solid-state or water-perfused manometry catheter...
The Biofeedback Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID to display, record, and analyze pressure and EMG signals from the pelvic floor in an interactive graphic f
...The Bile Reflux Analysis for POLYGRAM NET® is ...This add-on allows medical professionals to upload... ambulatory bile reflux recorder. The primary diff...sorbance of a certain wavelength of light correspo...
Medicine Products: